In this Phase 1 project we examined the feasibility of our approach. Regarding the technical feasibility, we demonstrated the efficiency of our CC-Coupler approach on reactions, which are theoretically possible, but no examples are provided in the literature, resulting compounds are biologically active and potentially interested by pharmaceutical companies. We successfully synthetized 6 new compounds and optimised the reaction conditions for them. In addition, we continued the reactor development and obtained graphical user interface (GUI). Furthermore, we optimised the catalyst formulation and its filling to cartridges. We also validated our business assumptions. We performed a detailed market study, including questionnaire and interviews with potential customers. The main result of this study is that the most important reason for choosing a catalyst is its performance. Thus, we must provide large variety of examples to prove the performance of our C-C coupler approach, to promote our sales. We carried out a detailed risk assessment and updated our IPR strategy.
As a result of the actions, we updated our business plan and defined main points of a subsequent Phase 2 application: work packages, objectives, tasks, and resources were defined.